MedPath

effects of intra-ovarian injection of autologous platelet rich plasma

Not Applicable
Conditions
diminished ovarian reserve.
infertility due to diminished ovarian reserve
N97.0
Registration Number
IRCT20101227005485N9
Lead Sponsor
Tabriz University of Medical Sciences
Brief Summary

Not available

Detailed Description

Not available

Recruitment & Eligibility

Status
Complete
Sex
Female
Target Recruitment
22
Inclusion Criteria

Antimullerian hormone(AMH) less than 1.1
number of antral follicles less than 5-7
history of cycle cancellation due to insufficient follicular growth
history of cycle cancellation due to less than 3 oocytes obtained
willingness to cooperate
Ages between 30 and 43 years

Exclusion Criteria

Immunoglobulin A deficiency
genital or non-genital cancers
treatment with anticoagulants
ovarian failure due to chromosomal abnormality
severe pelvic adhesion
non-acceptance or cooperation of the patient

Study & Design

Study Type
interventional
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
umber of oocytes obtained. Timepoint: Immediately after ovarian puncture before and 2 months after injection of platelet-rich plasma (PRP). Method of measurement: Under a microscope by an embryologist.;Follicular Stimulating Hormone (FSH) and Luteinizing Hormone (LH) day two or three of menstruation. Timepoint: Cycle before and 2 months after injection of platelet-rich plasma. Method of measurement: electrochemiluminescence.;Antimulerian hormone. Timepoint: Cycle before and 2 months after injection of platelet-rich plasma. Method of measurement: electrochemiluminescence.;Comparison of serum estradiol levels on the day of ovulation triggering. Timepoint: Cycle before and 2 months after injection of platelet-rich plasma. Method of measurement: electrochemiluminescence.
Secondary Outcome Measures
NameTimeMethod
umber of 4 to 8 cells embryos. Timepoint: 2 to 3 days. Method of measurement: With a microscope by an embryologist.
© Copyright 2025. All Rights Reserved by MedPath